Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
27.07
-0.03 (-0.11%)
At close: Feb 21, 2025, 4:00 PM
27.08
+0.01 (0.04%)
After-hours: Feb 21, 2025, 5:59 PM EST
Edgewise Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
88
Market Cap
2.56B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
EWTX News
- 4 weeks ago - Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development - Business Wire
- 5 weeks ago - Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025 - Business Wire
- 6 weeks ago - Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 - Business Wire
- 7 weeks ago - Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data - Seeking Alpha
- 2 months ago - Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease - Benzinga
- 2 months ago - Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) - Business Wire
- 2 months ago - Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research - Business Wire
- 3 months ago - Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 - Business Wire